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Abstract
There are an estimated 10.6 million incident cases of syphilis worldwide each year. We highlight some persistent
challenges and emerging trends in the clinical management of syphilis with a particular focus on therapy, serology,
diagnostics, and prevention. Decades after the introduction of penicillin, the optimal management of early syphilis
continues to be a controversial topic, particularly in the setting of HIV co-infection. Similarly, the need for routine
lumbar puncture in HIV co-infected asymptomatic persons is an unanswered question. Despite advances in both
automation and point-of-care diagnostics, we continue to rely on indirect measures of disease activity to manage this
infection. As syphilis rates in some populations continue to rise, novel and effective prevention strategies are needed.
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Review
Worldwide, there are an estimated 10.6 million incident
cases of syphilis each year [1]. Recent increases in rates
of syphilis have been observed in high-income countries
among men who have sex with men (MSM), many of
whom are HIV co-infected [2–4]. While strict testing and
treatment guidelines have significantly decreased morbid-
ity and mortality of congenital syphilis in high-income
countries, syphilis infection in pregnancy remains a sig-
nificant cause of adverse pregnancy outcomes in many
others [5, 6]. We were invited by the editors of BMC
Infectious Diseases to contribute a review on current chal-
lenges in the management of syphilis. In this review,we
highlight some emerging trends and persistent challenges
in the clinical management of syphilis with a particular
focus on therapy, serology, diagnostics, and prevention.
Therapy
Decades after the introduction of penicillin, the opti-
mal management of early syphilis continues to be a
controversial topic, particularly in the setting of HIV
co-infection. Currently, most major clinical guidelines
recommend similar treatment regimens for the various
stages of syphilis (Table 1). Penicillin continues to be
the drug of choice to treat all stages of syphilis in all
populations with tetracyclines and cephalosporins
acceptable alternate agents for some stages in non-
pregnant persons [7]. In general, the emergence of drug
resistance has precluded recommending macrolides for
the routine treatment of early syphilis [8, 9].
Although most guidelines recommend similar treatment
regimens for HIV-infected and uninfected persons with
syphilis, debate has centered on whether enhanced ther-
apy provides improved clinical or serological outcomes for
HIV-co-infected persons [10–12]. The predilection for the
development of early symptomatic neurosyphilis among
HIV-infected persons [13, 14] and data showing that a
single dose of 2.4 MU of benzathine penicillin G (BPG)
may be insufficient to clear Treponema pallidum from the
CSF of HIV-infected persons with early syphilis [15] have
fueled this debate. Particular interest has focused on en-
hanced therapy using three intramuscular doses of 2.4
MU of BPG instead of one. In the pre-HIV era, three
doses of 2.4 MU BPG were recommended as an alternate
treatment regimen for neurosyphilis [16]. In the early
1980’s its use was abandoned, not because of lack of
efficacy, but because it did not achieve consistent trepone-
micidal penicillin concentrations in the CSF [17]. Results
of retrospective studies comparing one versus multiple
doses of BPG were inconsistent [18]. The only published
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Table 1 Treatment of syphilis: US, UK and European recommendations













2.4 million units IM single
dose
Benzathine penicillin G
2.4 million units IM single
dose or Procaine
penicillin G 600 000 units
IM q24h for 10 days
Benzathine penicillin G
2.4 million units IM single
dose
Doxycycline 100 mg or PO
q12h for 14 days
Ceftriaxone 1-2 g IM q24h
for 10 days
Doxycycline 100 mg or PO
q12h for 14 days
Erythromycin 500 mg or PO
q6h for 14 days Ceftriaxone
500 mg IM or daily for
10 days Amoxicillin 500 mg
PO q6h plus Probenecid
500 mg or po q6h for
14 days
Procaine penicillin
600 000 units IM or daily
for 10-14 days Doxycyc-
line 200 mg or daily orally
for 14 days Ceftriaxone
500 mg-1 g IM or IV daily
for 10 days Azithromycin
2 g orally single dose
Late syphilis (latent




2.4 million units IM
weekly for 3 weeks
Benzathine penicillin G
2.4 million units IM or
weekly for 3 weeks
Procaine penicillin 600
000 units IM q24h for
17 days
Benzathine penicillin G
2.4 million units IM
weekly for 3 dose
Doxycycline 100 mg PO
q12h for 28 days
Doxycycline 100 mg or po
q12h for 28 days Amoxicillin
2 g PO q8h plus
probenecid 500 mg or po
q6h for 28 days
Procaine penicillin 600
000 units IM or daily
during 17-21 days Doxy-
cycline 200 mg PO daily
during 21-28 days
Neurosyphilis Aqueous crystalline
penicillin G 3-4 million
units IV q4h for 10-14
days
Procaine penicillin 1.8-2.4
million units IM q24h plus
probenecid 500 mg or po
q6h for 17 days Benzyl
penicillin 3-4 million units
IV q4h for 17 days
Benzyl penicillin 3-4
million units IV q4h for
10-14 days
Ceftriaxone 2 g IM or IV
q24h for 10-14 days
Doxycycline 200 mg po
q12h for 28 days Amoxicillin
2 g PO q8h plus
probenecid 500 mg or PO
q6h for 28 days Ceftriaxone
2 g IM or IV q24h for 10-14
days
Ceftriaxone 1-2 g or IV
daily during 10-14 days
Procaine penicillin 1.2-2.4
million units IM daily and
Probenecid 500 mg po
q6h for 10-14days















randomized controlled trial used a non-standard regimen
for neurosyphilis. It was also underpowered to address
the question in HIV-infected persons [19]. Recently,
two studies tried to address the question. The first, a
prospective multicenter Taiwanese study comparing 1
vs. 3 doses of BPG in HIV-infected patients, found no
statistically significant differences in serological re-
sponses at 6 and 12 months between the two groups
in the per protocol analysis, though a carry-forward
analysis did suggest improved serological outcomes fa-
voring the three dose group [20]. The second study, a
retrospective review of 478 cases of early syphilis in
HIV-infected patients followed in the US Military HIV
Natural History Study, found no statistically signifi-
cant difference in serologic response at 13 months in
those receiving one dose of BPG versus those receiv-
ing ≥ 2 doses of BPG [21]. Neither study assessed clin-
ical outcomes (e.g. development of early neurosyphilis)
in a systematic way. As such, the question of enhanced
therapy remains unanswered. Despite the fact that US
guidelines are clear and unambiguous about single
dose penicillin to treat early syphilis among HIV in-
fected persons, many clinicians continue to use en-
hanced therapy [22].
Serologies
T. pallidum cannot be cultured in the laboratory and
the performance characteristics of direct molecular diag-
nostics are limited [23–27]. Consequently, diagnosis and
monitoring of treatment responses depend largely on
serological testing. (The use of darkfield microscopy for
the diagnosis of early syphilis using specimens from
genital lesions, and the use of PCR testing on these
lesions, which is even more sensitive, are rarely per-
formed outside of specialized settings). The reliance on
these indirect tests that may not necessarily reflect
underlying disease activity has generated significant
challenges in the management of syphilis [28].
The serofast state
Patients who fail to achieve a 4-fold (i.e. two-dilution)
decline in nontreponemal [i.e. Venereal Diseases
Research Laboratory (VDRL) or Rapid Plasma Reagin
(RPR)] antibody titers, or those who have adequate
serologic decline but do not completely revert from
positive to negative have been referred to as ‘serofast’
[7]. The definition is broad and it is unclear if both
categories should be grouped together. In this section,
we define ‘serofast’ as those who do not achieve a
four-fold decline in titers following stage-appropriate
therapy [29].
The clinical importance of the serofast state was
clearly documented in the pre-antibiotic era. During
that time, 30 % of patients with early syphilis who were
‘Wasserman fast’ (the Wasserman test was a nontrepo-
nemal predecessor to the RPR and VDRL) developed
late neurologic complications, though this was not seen
in latent syphilis [30]. In the modern era, the optimal
approach to managing a patient who fails to achieve a
four-fold decline in nontreponemal antibody titers (and
who was not reinfected) is not known. In one study,
among 13 HIV-infected patients with serologic evidence
of syphilis whose serologic titers failed to decline ad-
equately a median of 287 days after therapy, 4 (31 %) were
found to have CSF abnormalities consistent with asymp-
tomatic neurosyphilis [31]. However another study did
not find an increased frequency of CSF abnormalities in
serofast HIV positive patients, but different definitions of
serofast serologies were used [32].
In some cases, a longer duration of follow-up is
necessary to document four-fold titer declines [33].
Indeed, persons with late syphilis [34] and those with
HIV not on antiretroviral therapy exhibit slower sero-
logical responses [32]. Persons with a lower initial
RPR may be more likely to remain serofast [29].
The short-term outcomes of treating patients who are
serofast have been described. One study demonstrated
that only a modest proportion (27 %) of HIV uninfected
serofast patients with early syphilis achieved a serologic
response 6 months after retreatment with one dose of
2.4MU BPG. There was no comparison group, so it is
difficult to conclude that this response was solely
attributable to retreatment [35]. Indeed, a study of pa-
tients with late latent syphilis found similar serological
responses between treated and untreated serofast
patients at the end of follow-up [33]. The more vexing
problem lies beyond the short-term serological re-
sponses: What are the long-term clinical consequences
of being serofast? At this time, the question remains
unanswered. Nonetheless, current CDC guidelines
recommend additional clinical and serological follow-
up in serofast patients and retreatment if follow-up
cannot be assured. Because treatment failure can be
the result of unrecognized CNS infection, CDC guide-
lines further recommend that CSF examination be
considered in these patients, if reinfection has been
ruled out [11].
Diagnostics
Fully automated assays that detect treponemal anti-
bodies and novel point-of-care (POC) diagnostics have
significantly impacted the field of syphilis diagnostics.
The reverse sequence algorithm
Increased availability of automated testing has recently led
many laboratories to switch to a reverse sequence algo-
rithm (RSA) in which a treponemal test is conducted first,
and if positive, followed by a confirmatory nontreponemal
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test [36]. Data on whether the RSA is cost effective in low
prevalence settings are mixed, with one study from
Canada finding that it was cost effective as compared with
the traditional algorithm, and one study from the US find-
ing that it was less cost effective [37, 38]. It does appear
that the RSA may facilitate the identification of latent
syphilis cases, though it may lead to more false positives
as well [39–41].
The use of the RSA rather than the traditional
nontreponemal-first algorithm does result in the identifi-
cation of a number of patients with serodiscordant
results (i.e. a positive treponemal test and a negative
nontreponemal test) [36]. This can occur in the setting
of 1) a false positive result, 2) early primary syphilis, 3)
the prozone phenomenon, 4) adequately treated past
syphilis or 5) untreated syphilis of long duration, as
nontreponemal test titers may decline over time even in
the absence of treatment. A second treponemal test
(preferably based on different antigens than the original
test) should be conducted to rule out the first possibility.
Persons with a confirmed positive treponemal test and a
negative nontreponemal test with a history of syphilis
treatment will require no further management unless
there is concern for reinfection [36].
Persons with serodiscordant serologies (i.e. confirmed
positive treponemal and persistently negative non trepo-
nemal tests) and no history of syphilis treatment present
several important clinical and public health questions,
particularly since they would likely be missed by the
traditional algorithm: What is their risk of transmitting
syphilis sexually? What is their risk of transmitting syphilis
vertically? What is their risk of progression to tertiary
syphilis? Based on studies from the pre antibiotic era, the
risk of sexual transmission in patients with late syphilis is
low [42]. Vertical transmission of syphilis has been docu-
mented at around 10 % in mothers with late latent disease
[43], while one study from 1922 reported that nearly 50 %
of infants born to seronegative mothers had probable or
definitive congenital syphilis [44]. However, the risk of ver-
tical transmission in serodiscordant women in the anti-
biotic era when patients are often routinely exposed to
beta lactam antibiotics, tetracyclines and macrolides for
reasons other than syphilis treatment, combined with the
use of significantly more sensitive modern nontreponemal
tests is unknown. A recent retrospective review suggests
that it is low [45]. The risk of progression to tertiary syph-
ilis in serodiscordant patients in the modern antibiotic era
is unknown and ethical and logistical challenges make it
unlikely that a study to address this issue will be forthcom-
ing. Two retrospective studies (Wohrl and Tuddenham)
suggest that the risk of neurosyphilis at the time of dis-
cordant test results is low. The risk of ophthalmic syphilis
may be higher, but the lack of objective measures for this
diagnosis makes drawing conclusions difficult [46, 47].
In general, persons with serodiscordant results and no
history of treatment should be assessed clinically, and
treated appropriately if signs or symptoms of active
syphilis are noted. If none are found, they should be
treated for syphilis of unknown duration with three
doses of 2.4MU of BPG weekly [48].
Point-of-care tests
Point of care (POC) tests are both simple and capable of
providing rapid results to guide clinical decisions during
the same encounter [49]. In recent years, a number of
rapid POC tests, which can deployed in a variety of set-
tings and provide results without specialized laboratory
equipment, have been developed for syphilis [50–53].
These include treponemal tests, combination treponemal
and nontreponemal tests, and multiplex tests that simul-
taneously test for syphilis antibodies and antibodies to
other infections such as HIV and hepatitis C [50, 53–55].
The majority of these tests rely on lateral flow technology.
Several are commercially available internationally. There
is currently one which is FDA approved for use in the
United States [52]. Recently, this test was granted a
Clinical Laboratory Improvement Amendment (CLIA)
waiver that will enable its use outside of traditional la-
boratory settings [56].
Efforts are underway to miniaturize current laboratory-
based technologies to enable rapid enzyme linked immuno-
sorbent assay (ELISA) tests to be run in the field. A recent
paper reports on the development and deployment of a
smartphone attachment, or “dongle,” which enables a trip-
lex ELISA test that provides results for HIV, treponemal,
and non-treponemal antibodies [57].
POC syphilis tests show considerable promise, how-
ever they do have some limitations. Most tests are based
on treponemal antibodies and therefore cannot distin-
guish between new and previously treated infections.
Combination treponemal and non-treponemal POC
tests, which may offer more information, do not provide
a non-treponemal titer with which to follow response to
treatment. Therefore, in settings where laboratory access
is available, POC tests may have less utility for general
use. In settings where access to laboratory facilities is
limited and where prevalence may be high, POC tests
may play an integral role in the diagnosis of syphilis. An
example is antenatal clinics, where the consequences of
overtreatment may be relatively small, but the conse-
quences of undertreatment may be catastrophic. A num-
ber of studies, including one large study in which POC’s
were introduced in project sites in six countries demon-
strated the feasibility of utilizing POC’s for antenatal
screening in a variety of rural and urban settings, and sig-
nificantly increased the proportion of pregnant women
screened and treated for syphilis [58]. Mathematical mod-
eling suggests that use of POC tests for antenatal syphilis
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screening in low resource settings is not only effective but
cost effective as well [59].
Point of care syphilis testing in low resource settings
may soon expand to include other specimens. Ho et al.
optimized the “Syphicheck” POC test made by Qualpro
Diagnostics, Goa, India, which was designed for use on
blood to be used on CSF, and obtained results similar to
those obtained with a CSF VDRL [60]. This could have
important implications for the diagnosis of neurosyphilis
in settings without extensive laboratory capabilities.
Neurosyphilis diagnostics
The diagnosis of neurosyphilis is challenging because
there is no gold-standard diagnostic test. It requires a
CSF examination, but the indications to perform this
procedure remain an issue of debate. CDC guidelines
currently recommend that a CSF examination be per-
formed in 1) persons with neurologic signs or symp-
toms 2) persons diagnosed with tertiary syphilis (e.g.
cardiovascular syphilis or late benign syphilis) and 3)
asymptomatic persons whose serologic titers do not
decline appropriately following recommended therapy
[11]. This last recommendation remains the source of
some controversy (as detailed above). The most con-
troversial question is the need for a CSF examination in
asymptomatic HIV-infected persons with CD4 cell
counts ≤ 350 cells/mm3 or RPR titers ≥ 1:32. The last
two criteria were noted to increase the probability of
symptomatic and asymptomatic neurosyphilis in this
population [31, 61]. At this time, data are lacking re-
garding the benefits of CSF examination in asymptom-
atic HIV-infected persons. Consequently, none of the
major guidelines have adopted a formal recommenda-
tion for this population.
Once the CSF examination is obtained, interpreting
the results may present further challenges. The CSF
VDRL is the most specific test but it is only about 50 %
sensitive. The CSF RPR is less sensitive than the CSF
VDRL and should not be used for diagnosis of neuro-
syphilis [62]. CSF treponemal tests are more sensitive
but less specific and a negative CSF treponemal test in
the setting of a moderate to high pre-test probability of
neurosyphilis does not rule out the diagnosis (reviewed
by Harding) [63, 64]. The CSF pleocytosis in syphilis is
lymphocyte predominant, and a cutoff of greater than or
equal to 5 cells/ml has been standard; however this may
have less specificity in HIV-infected persons [65].
Novel neurosyphilis diagnostics are being sought. Sev-
eral papers have evaluated CSF CXCL-13, a B-cell chemo-
attractant, as a diagnostic test for neurosyphilis [66–68].
Marra et al. examined serum and CSF concentrations of
CXCL-13 in 199 HIV-positive patients with early syphilis
who were referred because of concern for neurosyphilis.
The CSF concentration of CXCL-13 as well as a CSF:
serum CXCL-13 ratio of >1 performed reasonably well
compared to the CSF VDRL [66].
Public health interventions
Despite effective treatment and promising new diagnos-
tics, syphilis rates have continued to increase in MSM,
most significantly in HIV-infected MSM. A number of
factors may be contributing to this, among them the
practice of serosorting and seropositioning, often in
place of conventional risk reduction preventive strategies
such as condom use. In this setting the increased rates
of unprotected anal intercourse, particularly in HIV
positive men, may be contributing to transmission of
syphilis and other STIs [69–71]. Given continued risk
behaviors and increasing incidence of syphilis, new pre-
vention strategies are needed. Some possible approaches
include frequent screening, novel approaches to case
finding, and consideration of chemoprophylaxis.
Frequent screening
Syphilis infection and reinfection rates in MSM and HIV
infected MSM are high, and identifying and treating
asymptomatic early infections may be important in
breaking the chain of transmission [72, 73]. Annual
screening of these populations has been shown to iden-
tify a significant number of asymptomatic infections
[74]. However, other studies suggest that implementing
more frequent screening in selected populations may
have added benefits. One study in which routine syphilis
serology was included with every blood test performed
as part of HIV monitoring among HIV positive MSM
attending a clinic in Australia found a marked increase
in identification of early syphilis cases [75]. Furthermore,
a study using mathematical models suggests that in-
creasing the frequency of screening in certain high-risk
target groups (such as MSM who have large numbers of
partners or engage in group sex) to every 3 months may
be critical to decreasing syphilis incidence [76]. Another
model suggests that increased coverage and frequency of
screening of HIV positive MSM may be cost effective [77].
Similarly, screening in incarcerated populations may be
high yield, [78] and may be cost effective as well [79].
Case finding: novel approaches
The internet and mobile devices are increasingly being
used to locate sex partners. New approaches that make
use of the internet and mobile phone texting technolo-
gies to assist in partner notification, contact tracing,
education, and testing must constantly evolve to reach
at-risk groups [80–82]. Several studies have associated
risk behaviors in MSM, including unprotected anal
intercourse, with use of novel social networking applica-
tions [83, 84]. A recent report described increased syph-
ilis testing with the use of a promotion campaign on the
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social networking site Grindr, which is often used by
MSM to find sexual partners [85].
Antibiotic prophylaxis and other approaches
While mass antibiotic treatment, conducted in outbreak
situations or high-prevalence settings, has had mixed
results in affecting the incidence of syphilis [86, 87],
targeted chemoprophylaxis of motivated high-risk indi-
viduals may be a reasonable strategy. A recent study
demonstrated that over 50 % of MSM surveyed would
be willing to take daily pills to decrease their risk of
syphilis infection, and over 75 % were willing to take
daily medication to decrease syphilis infections in the
gay community. Mathematical modeling suggested that
chemoprophylactic doxycycline, either widely distrib-
uted or targeted to certain high risk MSM, could
significantly reduce new cases of syphilis in the MSM
community, though cases would rebound once the
intervention was stopped [88]. A recent pilot study
showed the feasibility of daily doxycycline in a small
group of high risk MSM. The study was not powered to
show a difference in syphilis incidence, but there was a
decrease in acute STIs in the group taking daily doxy-
cycline [89]. This is an intriguing new approach, though
larger studies will be required, and several important
issues must be carefully weighed before moving
forward, such as adherence, impact on the microbiome,
emergence of drug resistance, and long-term drug tox-
icities. Finally, a recent study showed that male circum-
cision was associated with a decreased risk of incident
syphilis in men and women [90].
Conclusions
Advances in diagnostics may have a significant impact
on reducing cases of congenital syphilis in resource-
limited settings, where rates of this devastating condition
are still very high. Whether these diagnostics can have a
meaningful impact on rising rates of syphilis among
MSM is unclear. Without a vaccine in sight, novel and
effective prevention strategies are sorely needed to com-
bat this infection.
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